Anti-EBV trial shows promise in Progressive MS

New Drug Shows Promise For Patients With Progressive Multiple SclerosisПодробнее

The Big Idea: Multiple Sclerosis Clinical Trial Shows PromiseПодробнее

Jakob Dupont, MD: Epstein-Barr Virus Targeted Agent ATA188 in Progressive MSПодробнее

Clinical trial for MS treatment shows promise in slowing disability progression.Подробнее

Jakob Dupont, MD: Phase 1 Data on Cell Therapy for Progressive MSПодробнее

ATA188 in EBV+ progressive multiple sclerosisПодробнее

Medication shows promise treating Progressive MSПодробнее

ATA188: an allogeneic EBV-specific T cell therapy for progressive MSПодробнее

EBV & MS risk at ACTRIMSПодробнее

Epstein Barr Virus and Multiple Sclerosis MSПодробнее

Episode 229: Evidence Shows MS Is Triggered by the Epstein-Barr Virus with Dr. Kassandra MungerПодробнее

Does Epstein-Barr Virus Cause MS? | Breaking MSПодробнее

MS Research Australia - Progress in MS Research Live Update 2018Подробнее

Adoptive transfer of EBV-specific T cells in patients with multiple sclerosisПодробнее

Ask an MS Expert: The Role of Epstein-Barr Virus in MSПодробнее

The evolving understanding of multiple sclerosis: EBV and silent progressionПодробнее

AM2020-Willmer-ID27Подробнее